摘要
目的观察恩度(重组人血管内皮抑素)联合培美曲塞方案二线治疗晚期非小细胞肺癌的近期疗效和不良反应。方法选择经病理组织学或细胞学确诊的一线化疗失败晚期非小细胞肺癌患者58例,随机分为恩度联合培美曲塞方案化疗组28例和单纯培美曲塞方案化疗组30例。恩度联合培美曲塞方案化疗组给予培美曲塞500mg/m2,第1d,恩度15mg,连用14d,休息1周。单纯化疗组仅给予常规培美曲塞方案化疗。21d为一周期,两周期治疗结束后参照WHO评价标准,对其近期疗效和不良反应进行评价。结果联合化疗组有效率ORR(CR+PR)为14.3%,单纯化疗组ORR为10.0%,两组比较差异无显著性意义(P>0.05)。联合化疗组疾病控制率DCR(CR+PR+SD)为57.1%明显高于单纯化疗组30.0%(P<0..05)。两组主要不良反应为消化道反应、骨髓抑制和脱发。恩度联合培美曲塞化疗组发生率分别为21.1%、5.3%和5.3%,单纯培美曲塞化疗组发生率分别为19.2%3、.8%和7.7%,两组相比发生率无显著性差异(P>0.05)。结论恩度联合培美曲塞方案安全有效,在晚期非小细胞肺癌的二线治疗中值得推荐。
Objective To observe the recent efficacy and side effects of Endostar combined with Alimta chemotherapy as the second line for advanced stage NSCLC.Methods Totally 58 advanced NSCLC patients confirmed by pathohistology or cytology were randomly divided into two groups：the Endostar combined with Alimta group（28 cases）and the simple Alimta chemotherapy group（30 cases）.Patients in combination chemotherapy group were treated with Alimta 500mg/m2,d1 and endostar 15mg,dl^14,1 week for rest.Patients in the simple chemotherapy group were only treated with Alimta.The recent efficacy and side effects were evaluated after 2 cycles according to WHO standard.Results The overall response rates（ORR） in the combination chemotherapy group and the simple chemotherapy group were 14.3% and 10.0%,which did not reach a significant difference（P〉0.05）.Disease control rate（DCR,CR＋PR＋SD） in combination chemotherapy group was 57.1%,which was significantly higher than 30.0% in simple chemotherapy group（P〈0.05）.Among the main toxicity,the incidence rates of gastrointestinal toxicity,bone marrow suppression and hair loss were 21.1%,5.3%and 5.3% in the combination chemotherapy group and 19.2%,3.8%and 7.7% in the simple chemotherapy group.There was not significant difference between the two groups（P〈0.05）.Conclusions Endostar combined with Alimta regimen is safe and effective,which should be recommended to treat advanced NSCLC as the second line.
出处
《医药论坛杂志》
2011年第12期63-65,共3页
Journal of Medical Forum
关键词
恩度
培美曲塞
化疗
非小细胞肺癌
Endostar
Alimta
Chemotherapy
Non-small cell lung cancer
作者简介
通讯作者：王瑞，E—mial：wangruihello@yahoo．com．cn
